Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010389 | 0.91 | HPGD (0.69) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL21952099 | 0.89 | NPSR1 (0.56) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL24209791 | 0.88 | ALDH1A1 (0.66) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL24210198 | 0.88 | KDM4E (0.64) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL21952012 | 0.86 | NPSR1 (0.56) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL24210197 | 0.86 | ALDH1A1 (0.83) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL24209903 | 0.83 | NPSR1 (0.68) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL21952093 | 0.83 | MEN1 (0.56) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL21952070 | 0.83 | MEN1 (0.61) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL31396394 | 0.83 | MEN1 (0.61) | ALDH1A1MAPK1NPSR1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880199-B1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUNDACION PUBLICA GALLEGA DE INVESTIG BIOMEDICA INIBIC (ES) | 2025-04-23 | — | — | EP | disclosed |
| CN-115768422-B | Ubiquitin ligase inhibitors for the treatment of cancer | 诺沃亚桑托斯教授基金会 | 2025-03-04 | — | — | CN | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| CN-115768422-A | Ubiquitin ligase inhibitors for the treatment of cancer | 诺沃亚桑托斯教授基金会 | 2023-03-07 | — | — | CN | disclosed |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
| CN-113677340-A | Compounds that selectively and efficiently inhibit Hakai-mediated ubiquitination as anti-cancer agents | 诺沃亚桑托斯教授基金会 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021229035-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2021-11-18 | — | — | WO | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020099652-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2020-05-22 | — | — | WO | disclosed |
| EP-3653208-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | Fundación Profesor Novoa Santos (ES) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653208-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | Fundación Profesor Novoa Santos (ES) | 2020-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | ALDH1A1 1206/4885MAPK1 3830/4885NPSR1 4628/4885 |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | ALDH1A1 967/4885MAPK1 762/4885NPSR1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.